Order of chemotherapy, radiation has no effect on breast cancer survival

October 30, 2006

For women who have had surgery for early breast cancer, it may not matter whether they receive follow-up chemotherapy before, after or during radiation therapy, according to a new review of studies.

A woman's chances of survival or seeing the cancer return are similar in all three cases, if radiation therapy and chemotherapy begin within seven months after surgery, the review concludes.

However, the studies suggest that certain toxic side effects in the blood and esophagus -- common in chemotherapy and radiation patients -- may be up to 44 percent more likely when the two therapies are delivered at the same time, said Dr. Brigid Hickey and colleagues at the Southern Zone Radiation Oncology Service in Brisbane, Australia.

The reviewers also note that most of the women in the studies were treated about 10 years ago. "As a result, the trials do not assess the modern types of radiotherapy and newer types of chemotherapy" and other anti-cancer drugs such as Herceptin, Hickey said.

Studies show that radiation therapy can reduce the risk of breast cancer returning in the treated breast and boost the likelihood of survival after breast cancer surgery. Doctors may also prescribe chemotherapy to women at high risk for having the cancer spread to other parts of the body after surgery, to reduce the risk of dying from breast cancer.

"However, the best sequence of administering these two types of therapy for early stage breast cancer is not clear," Hickey said.

"As far as I know, there are few good randomized trials evaluating the different timing of radiation. This is one of the problems about deciding on what the best approach is here," said Dr. Tim Whelan, a radiation oncologist who specializes in breast cancer treatment at McMaster University in Ontario, Canada.

Hickey and colleagues found only three high-quality studies, comprising 1,097 patients, that compared different sequences of radiation and chemotherapy after breast cancer surgery.

The finding may reassure those who begin chemotherapy while waiting for radiation treatment, which is limited in many parts of the world, the Cochrane researchers said.

"The delivery of chemotherapy first allows patients to continue with their treatment while they wait for radiotherapy to start, and this may make management of the waiting lists for radiotherapy easier," Hickey said.

Whelan said his clinical practice usually gives chemotherapy first followed by radiation. His practice follows a suggestion from an earlier study and "a clinical impression" that giving chemotherapy first reduces the risk that the cancer will reappear in a distant part of the body. But Whelan acknowledged that the risk of recurring cancer in the breast may be slightly higher when radiation is delayed.
-end-
By Becky Ham, Science Writer Health Behavior News Service

The Hickey review was supported by the Princess Alexandra Hospital Cancer Collaborative Group in Australia.

FOR MORE INFORMATION
Health Behavior News Service: (202) 387-2829 or www.hbns.org.

Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. The Cochrane Database of Systematic Reviews 2006, Issue 4.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Center for Advancing Health

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.